[go: up one dir, main page]

WO1998018509A1 - Procede et appareil d'amelioration de la compatibilite des plaquettes dans un dispositif - Google Patents

Procede et appareil d'amelioration de la compatibilite des plaquettes dans un dispositif Download PDF

Info

Publication number
WO1998018509A1
WO1998018509A1 PCT/US1997/019191 US9719191W WO9818509A1 WO 1998018509 A1 WO1998018509 A1 WO 1998018509A1 US 9719191 W US9719191 W US 9719191W WO 9818509 A1 WO9818509 A1 WO 9818509A1
Authority
WO
WIPO (PCT)
Prior art keywords
pump
tubing
tubing loop
force
platelets
Prior art date
Application number
PCT/US1997/019191
Other languages
English (en)
Inventor
Bruce W. Gibbs
Original Assignee
Cobe Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cobe Laboratories, Inc. filed Critical Cobe Laboratories, Inc.
Publication of WO1998018509A1 publication Critical patent/WO1998018509A1/fr

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
    • F04B43/00—Machines, pumps, or pumping installations having flexible working members
    • F04B43/0009—Special features
    • F04B43/0054—Special features particularities of the flexible members
    • F04B43/0072—Special features particularities of the flexible members of tubular flexible members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/068—Use of macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/10—Location thereof with respect to the patient's body
    • A61M60/104—Extracorporeal pumps, i.e. the blood being pumped outside the patient's body
    • A61M60/109—Extracorporeal pumps, i.e. the blood being pumped outside the patient's body incorporated within extracorporeal blood circuits or systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/20—Type thereof
    • A61M60/247—Positive displacement blood pumps
    • A61M60/253—Positive displacement blood pumps including a displacement member directly acting on the blood
    • A61M60/268—Positive displacement blood pumps including a displacement member directly acting on the blood the displacement member being flexible, e.g. membranes, diaphragms or bladders
    • A61M60/279—Peristaltic pumps, e.g. roller pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/30—Medical purposes thereof other than the enhancement of the cardiac output
    • A61M60/36—Medical purposes thereof other than the enhancement of the cardiac output for specific blood treatment; for specific therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/10—Location thereof with respect to the patient's body
    • A61M60/104—Extracorporeal pumps, i.e. the blood being pumped outside the patient's body
    • A61M60/109—Extracorporeal pumps, i.e. the blood being pumped outside the patient's body incorporated within extracorporeal blood circuits or systems
    • A61M60/113—Extracorporeal pumps, i.e. the blood being pumped outside the patient's body incorporated within extracorporeal blood circuits or systems in other functional devices, e.g. dialysers or heart-lung machines

Definitions

  • the present invention relates to extracorporeal tubing sets for use during blood processing including harvesting of blood components. More particularly, the present invention relates to a peristaltic pump tubing loop disposed in the pump raceway, formed from a polymeric material having a surface modifying additive for reducing clumping in concentrated platelet solutions following transport of the concentrated platelet solution through the peristaltic pump tubing loop.
  • whole blood is removed from a donor, anticoagulant is added to the blood to prevent coagulation, the whole blood is fractionated into various blood components, the desired blood components are harvested and the remaining blood components returned to the donor.
  • Whole blood or particular blood components may also be harvested from a plurality of donors and pooled together. Pooled whole blood may be further fractionated into various blood components. Often platelets are the blood component being harvested.
  • Platelets are harvested during an apheresis procedure at high concentrations. It has been observed, however, that clumps are present in concentrated platelets solutions after the solution has been pumped through a tubing loop of a peristaltic pump. In contrast, this clumping is not observed, or is not detectable, in whole blood when the whole blood is pumped through the tubing loop of peristaltic pumps throughout the blood processing system. Therefore it appears that the concentrated platelet solution is more susceptible to the formation of clumps. Furthermore, while these observed clumps tend to mimic the appearance of thrombi or activated platelet aggregates, they do not exhibit the characteristics. For example, the observed platelet clumps occur in the absence of thrombin and in such concentrated platelet solutions in the absence of activated platelet aggregates.
  • thrombin in extracorporeal blood is often indicative of blood coagulation and the formation of thrombi.
  • An active thrombin molecule is formed when prothrombin is cleaved to thrombin, resulting in an active thrombin molecule and a 1.2 kilodalton protein fragment. Detection of this 1.2 kilodalton fragment correlates with the presence of active thrombin in the tested blood sample and the formation of thrombi. Clumping in concentrated platelet solutions during plateletpheresis has been observed in the absence of this 1.2 kilodalton fragment.
  • Platelet activation and aggregation comprises a complex series of reactions and stages.
  • One indicator of platelet activation is the detection of the GMP-140 protein that is typically present on the internal membranes of platelets.
  • the GMP-140 protein is generally not detectable on intact platelets.
  • the GMP-140 protein appears on the external platelet surface where it can be assayed and detected. Clumping in concentrated platelet solutions has been observed even where elevated GMP-140 levels were not detected.
  • Clumping present in concentrated platelet solutions where there is detection of only normal amounts or not elevated amounts of the 1.2 kilodalton fragment or the GMP-140 protein has been observed to be reversible.
  • Such clumps in concentrated platelet solutions are considered reversible because they disappear without filtration, enzymatic, chemical or thermal intervention.
  • Reversible clumping in concentrated platelet solutions remains problematic. Such clumping may indicate a form of blood trauma. Further, such clumping is problematic because it mimics the appearance of thrombi or activated irreversible platelet aggregates. Thrombi and activated platelet clumps are not reversible and filtration, thermal, or enzymatic reactions are required to remove them after formation.
  • a technician may, therefore, mistake the reversible platelet clumps for thrombi or activated platelet aggregates.
  • the technician may filter the harvested platelets to remove the supposed thrombi or activated platelet aggregates, thereby reducing the number of platelets ultimately harvested in a given procedure.
  • a technician, mistaking the reversible platelet clumps for thrombi or aggregated platelets may increase the concentration at which anticoagulant is delivered to the extracorporeal tubing set in an attempt to prevent the supposed blood coagulation.
  • a significant aspect of the present invention is a method and apparatus for preventing reversible clumping in concentrated platelet solutions during plateletpheresis procedures .
  • Another important aspect of the present invention is a method and apparatus for preventing clumping of concentrated platelet solutions when such solutions are transported through the tubing loop of a peristaltic pump.
  • an improved peristaltic pump design for the platelet collection pump is provided.
  • the present invention provides a tubing loop for the raceway of a peristaltic pump comprising a base polymer that includes a surface modifying additive. It is preferred that the surface modifying additive comprise a block copolymer of polycaprolactone and polysiloxane . Also provided is a method for reducing reversible clumping.
  • FIG.l illustrates the flow path for a hypothetical apheresis procedure that includes fractionating the blood into its components including a high platelet content component .
  • FIG. 2 is a top cut away of the rotor assembly of the present invention having a single spring loading each roller element.
  • FIG.l The flow paths for a hypothetical blood apheresis procedure, which includes plateletpheresis, are shown in FIG.l.
  • the flow paths in FIG.l are not intended to depict any actual apheresis procedure, but instead are intended to be exemplary of the possible flow paths used for a variety of possible procedures that include harvesting platelets. Actual procedures may not include all the flow paths shown in FIG.l, but rather a subset of the depicted flow paths and may include additional flow paths (not shown) .
  • FIG. 1 illustrates a dual needle procedure. It will be recognized by those skilled in the art that the present invention may be used with a single needle procedure as well. Further, the present invention may be used where whole blood is removed from a donor and stored for later separation into blood components.
  • Fig. 1 is schematic and it is understood that the flow paths pass through the tubing loops of the various pumps .
  • Whole blood is removed from a donor into and through an inlet line 12.
  • An anticoagulant such as citrate based ACD-A, is pumped from an anticoagulant reservoir 14 by an anticoagulant pump 16 through an anticoagulant line 18 into the inlet line 12 of an extracorporeal tubing set 20.
  • the extracorporeal tubing set 20 may be formed out of any of the conventional polymeric materials, well known to those skilled in the art, typically used for the construction of medical tubing sets.
  • PVC polyvinyl chloride
  • the whole blood with added anticoagulant is pumped by an inlet pump 22 to a separator system 24, also referred to as a blood processor, for separating the whole blood into fractionated components.
  • the separator system 24 may be a centrifuge of the continuous flow type, such as the centrifuge used with the COBE SPECTRA ® brand apheresis system manufactured by COBE BCT, Inc.
  • the separator system 24 may also be any other system capable of separating blood into its components such as other types of continuous and batch centrifuge systems and membrane separation systems.
  • the separator system 24 may include a batch processor used in a laboratory or manufacturing setting where individual or batched units have been collected and stored for later processing.
  • the present invention may also be adaptable to other extracorporeal circulation systems or medical devices that contact concentrated platelet solutions.
  • the separator system 24 fractionates the whole blood into a variety of blood components such as plasma, platelets, white blood cells, red blood cells or any combination of them.
  • the plasma is drawn off by a plasma pump 26 to a collect line 28 and into a collect bag 30.
  • Platelets are drawn off by a platelet pump 32 to a collect line 34 and into a platelet collect bag 36.
  • a return line 41 returns to the donor any components that are not collected.
  • In fluid communication with the return line 41 there may be a replacement line 38 although it is understood that a replacement fluid may also not be used.
  • a replacement fluid pump 40 pumps replacement fluid if used, such as sterile saline or blood plasma, from a replacement fluid reservoir 42 into the replacement fluid line 38.
  • the outlet end of the return line 41 enters the donor.
  • the flow through the various pumps is monitored and controlled using a microprocessor based controller 42 connected to the various peristaltic pumps by conventional electrical interconnects 44, 46, 48, 50, and 52.
  • the pumps are any conventional peristaltic pump well known to those skilled in the art.
  • Platelets are generally present in the whole blood of a typical, healthy donor at a concentration of around 200,000 to 400,000 platelets per cubic microliter.
  • the separator system 24 will typically fractionate and concentrate the platelets from whole blood into a concentrated platelet solution comprising platelets and blood plasma.
  • This concentrated platelet solution may range from 400,000 to 20,000,000 platelets per microliter with an incorporated amount of anticoagulant.
  • the platelet pump 32 draws the concentrated platelet solution through the platelet collect line 34 into the platelet collect bag 36.
  • the present invention prevents the clumping that is often observed in conventional extracorporeal tubing sets in the platelet collect line 34 of concentrated platelet solution following transport of the solution through the platelet pump 32. Referring next to FIG.
  • the platelet pump 32 is any conventional peristaltic pump well known by those skilled in the art, including those having spring loaded roller elements.
  • the tubing loop may be solvent bonded into sockets in a mounting cassette as is well known if needed.
  • the present invention prevents clumping in concentrated platelet solutions often observed after such solutions are pumped through the tubing loop 54 of the platelet pump 32 by forming the tubing loop 54 out of a base polymer having a surface modifying additive.
  • the base polymer, of tubing loop 54 may comprise polyurethane, polyurea, polyvinylchloride, polyamide, epoxy resin, phenoxy resin, polyester, polyester-polyether copolymer, acrylonitrile-butadiene-styrene resin, styrene- acrylonitrile resin, polycarbonate, styrene-maleic anhydride copolymer, polymethyl methacrylate, or polyolefin .
  • the surface modifying additive of the present invention comprise the linear block copolymer polycaprolactone and polysiloxane.
  • Compositions of this surface modifying additive are commercially available from Thoratec Laboratories Corporation (Berkeley, California) .
  • the nominal molecular weights (number average) of the polysiloxane blocks suitable for use herein range from about 1000 to about 5000, while the nominal molecular weights of the caprolactone blocks range from about 1000 to about 10,000.
  • Suitable surface modifying materials would be those that would form with the base polymer. It is necessary to use a surface modified polymer that does not increase the formation of thrombin, or increase the formation of activated platelet aggregates. It is also necessary that the surface modified polymer prevent reversible clumping in the concentrated platelet solution without other adverse effects.
  • the base polymer may be melt blended using the polycaprolactone-polysiloxane as an additive copolymer.
  • Polycaprolactone-polysiloxane may also be added to the monomeric materials from which the base polymer will be formed.
  • the base polymer is polymerized a physical mixture of the polycaprolactone- polysiloxane and the base polymer will form.
  • Polycaprolactone-polysiloxane may also be used as a prepolymer, and thereby be chemically incorporated into the base polymer.
  • PVC polyvinylchloride
  • tubing comprising 1% SMA 422, SMA 422 having a nominal configuration of 2000-2000-2000 of polycaprolactone-polysiloxane-polycaprolactone, is one tubing suitable for forming the tubing loop 54 of the present invention.
  • This tubing, Plastron 5120-68 tubing having 1% SMA is commercially available from Plastron (City of Industry, California, U.S.A.) under the name
  • the spring loaded rotor assembly 56 may be modified to reduce the force used to occlude the tubing loop 54. This force is applied when the roller elements 58, 60 press the tubing loop 54 against the wall of the peristaltic pump raceway 62.
  • occlusion force is meant the force inserted on the tubing by the roller set such that it collapses the tubing; that is, the force necessary to collapse the tubing such that there can be no back flow.
  • an occlusion force of about 12 pounds has been used to occlude a tubing loop in the raceway of a peristaltic pump, where the tubing loop is composed of PVC (sold as Natvar 610) having approximately 0.287 cm internal diameter and approximately 0.094 cm wall thickness without any SMA.
  • an occlusion force of about 15 pounds has been used to achieve occlusion, as described above, for PVC tubing, in a tubing loop composed of Plastron 5120-68 PVC tubing having 1% SMA (Plastron 808) with approximately 0.287 cm internal diameter and 0.094 cm wall thickness.
  • PVC tubing (Natvar 610) occluded by an occlusion force of about 12 pounds and PVC tubing having 1% SMA (Plastron 808) occluded by an occlusion force of about 15 pounds will be defined as being occluded by the standard force for occlusion or the typically used force for the particular tubing.
  • the standard force for occlusion is typically achieved by attaching two compressive springs (not shown) , to each roller element of the peristaltic pump.
  • the compressive springs force the roller elements towards the raceway wall thereby fully occluding the tubing loop with the standard force for occlusion.
  • the second preferred embodiment of the present invention uses a single compressive spring 64, 66 attached to each roller element 58, 60 (as shown in figure 2) to occlude the tubing loop 54.
  • the optimal force allows for tolerances due to variances in raceway, spring, rotor parts, roller and tubing.
  • the use of a single spring is in contrast to the use of two-compressive springs by prior pumps for each roller element.
  • the rotor assembly 56 and attachment of compressive springs 64, 66 to roller elements 58, 60 are conventionally designed as is well known by those skilled in the art.
  • the single spring for each roller can be adjusted to provide sufficient force to occlude the tubing. It is also understood that other modifications could be made to the pump to achieve the optimal force.
  • the optimal occlusion force using the single spring is about 7 to 8 pounds .
  • the use of the minimum or optimal force for occlusion reduces trauma to the platelets and clumping associated with the trauma.
  • Platelets were collected from a single donor at approximately 3 million platelets per ⁇ l during an apheresis procedure using the COBE SPECTRA ® brand apheresis system manufactured by COBE BCT, Inc.
  • a syringe pump was inserted in the tubing of the COBE SPECTRA ® apheresis system at a point before the tubing loop of the platelet collect pump to collect the concentrated platelets .
  • the concentrated platelet solution was then pumped through the tubing loops of three parallel peristaltic pumps.
  • the first parallel peristaltic pump (Pump 1) comprised conventional PVC (Natvar 610) tubing occluded with the standard force for occlusion.
  • the second parallel pump (Pump 2) comprised 1% SMA (Plastron 808) tubing occluded with the standard force for occlusion.
  • the third parallel pump comprised 1% SMA (Plastron 808) tubing occluded with approximately the optimal determined force for occlusion. All the tubing tested had approximately 0.287 cm internal diameter and a 0.094 cm wall thickness.
  • the three parallel pumps were connected together to a main tube from which three separate tubes extending therefrom. Each of the three separate tubes passed through a different one of the parallel pumps.
  • the concentrated platelet solution was delivered simultaneously to each parallel pump by introducing the concentrated solution as a single bolus into the main connector tube.
  • the concentrated platelet solution was processed through each pump at a rate of 2 milliliters/minute and 10 milliliters of post-pump concentrated platelet solution was collected into a separate syringe for each pump.
  • the post-pump solutions were allowed to rest undisturbed for 1 to 5 minutes to allow the post-pump clumps to accumulate at the bottom of the syringe.
  • the post-pump solutions were visually observed for clumping and videotaped for detailed visual inspection.
  • Clumping observed in the platelet solution from the first peristaltic pump (Pump 1) was pronounced.
  • Clumping observed in the platelet solution of the second pump (Pump 2) was less than that observed in the first pump.
  • Clumping in the solution of the third pump (Pump 3) was barely detectable.
  • the clumps were then quantified by measuring the platelet concentration of the clear fluid on the top 2 milliliter (the supernatant) , and the concentration of the remaining milliliter solution after the clumps were resuspended.
  • the sample of the supernatant indicates the nonclumped platelets. This concentration multiplied by 10 is the total nonclumped platelets.
  • the platelet number of the adjusted supernatant was subtracted from the number obtained for the resuspended sample to obtain the number clumped. This number divided by the total of all platelets is the percentage clumped.
  • the total number of all platelets is the number of platelets in the 2 milliliters supernatant sample plus the quantity in the 8 milliliter resuspended sample. The total minus the nonclumped platelets gives the number of clumped platelets.
  • Table 1 The results are shown in Table 1.
  • GMP-140 protein is an indicator of platelet activation. When platelets are activated, the GMP-140 protein is released and can be detected and assayed.
  • the pump configurations for Table 2 are a pump one (1) configuration of PVC Natvar 610 at a 12 pound force for occlusion; a pump two (2) configuration having a tubing loop of Plastron 808 (1% SMA) set at a 15 pound force for occlusion; and a pump three (3) configuration having a tubing loop of Plastron 808 (1% SMA) at a reduced 7 to 8 pound force for occlusion. All three tubing loops had approximately 0.287 cm internal diameter and 0.094 cm wall thickness. Table 2 below shows the results for the different pump configurations. Table 2
  • the post pump or after pump samples of platelet solution identified above were also tested for the presence of a 1.2 kilodalton protein fragment that is cleaved from prothrombin when thrombin is formed.
  • the pump configurations were as given for the detection of the GMP-140 protein above.
  • An ELISA (enzyme linked sorbent) assay was run on each sample to detect the 1.2 kilodalton fragment.
  • the results of the assay for each of the respective pump configurations identified above are given in Table 3.
  • the table shows that the three pump configurations had virtually indistinguishable levels of PF 1.2 which were within normal blood levels of less than 3 nanomolar/liter for PF 1.2. Therefore use of 1% SMA or an optimal force for occlusion does not appear to increase the presence of thrombin in an adverse manner.
  • the same method for gathering samples and determining platelet concentrations as set forth above concerning the Tubing Comparison Tests was used to compare the dual spring and single spring pump operation.
  • the Plastron 808 (1% SMA) tubing was used for both pumps.
  • the single spring pump configuration was the Plastron 808 (1% SMA) tubing occluded with an optimal force of approximately 8 pounds.
  • the double spring pump configuration was the Plastron 808 (1% SMA) tubing occluded with a standard force of approximately 15 pounds. Both tubings had 0.287 cm internal diameter and 0.094 cm wall thickness.
  • the percent of clumping using each peristaltic pump configuration was determined and the results are set forth in Table 4 below for four different collection runs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mechanical Engineering (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • External Artificial Organs (AREA)

Abstract

L'invention concerne un appareil et un procédé permettant de réduire l'aggrégation plaquettaire dans une solution concentrée de plaquettes. Une pompe (32) pourvue d'une tubulure en boucle (54) d'un polymère modifié en surface permet de pomper la solution concentrée de plaquettes. L'aggrégation plaquettaire est ainsi réduite dans la solution concentrée après son transport dans la tubulure en boucle (54) de la pompe.
PCT/US1997/019191 1996-10-28 1997-10-23 Procede et appareil d'amelioration de la compatibilite des plaquettes dans un dispositif WO1998018509A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73873096A 1996-10-28 1996-10-28
US08/738,730 1996-10-28

Publications (1)

Publication Number Publication Date
WO1998018509A1 true WO1998018509A1 (fr) 1998-05-07

Family

ID=24969251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019191 WO1998018509A1 (fr) 1996-10-28 1997-10-23 Procede et appareil d'amelioration de la compatibilite des plaquettes dans un dispositif

Country Status (1)

Country Link
WO (1) WO1998018509A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109734854A (zh) * 2018-11-27 2019-05-10 四川大学 一种可在环氧树脂中自发构筑特定纳米结构的嵌段共聚物及其在环氧树脂高性能化中的应用
EP3763312A1 (fr) * 2013-10-28 2021-01-13 Boston Scientific Scimed, Inc. Système de gestion de fluide
US12029683B2 (en) 2018-02-22 2024-07-09 Alcon Inc. Ocular implant and delivery system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562352A (en) * 1968-09-06 1971-02-09 Avco Corp Polysiloxane-polyurethane block copolymers
US4564342A (en) * 1983-07-25 1986-01-14 Fresenius Ag Peristaltically operating roller pump and pump rotor therefor
US4663413A (en) 1985-01-04 1987-05-05 Thoratec Laboratories Corp. Polysiloxane-polylactone block copolymers
US4963595A (en) 1985-01-04 1990-10-16 Thoratec Laboratories Corporation Polysiloxane-polylactone block copolymers
US5235003A (en) 1985-01-04 1993-08-10 Thoratec Laboratories Corporation Polysiloxane-polylactone block copolymers
WO1994025086A1 (fr) * 1993-04-27 1994-11-10 Haemonetics Corporation Appareil et procede de pherese

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562352A (en) * 1968-09-06 1971-02-09 Avco Corp Polysiloxane-polyurethane block copolymers
US4564342A (en) * 1983-07-25 1986-01-14 Fresenius Ag Peristaltically operating roller pump and pump rotor therefor
US4663413A (en) 1985-01-04 1987-05-05 Thoratec Laboratories Corp. Polysiloxane-polylactone block copolymers
US4963595A (en) 1985-01-04 1990-10-16 Thoratec Laboratories Corporation Polysiloxane-polylactone block copolymers
US5235003A (en) 1985-01-04 1993-08-10 Thoratec Laboratories Corporation Polysiloxane-polylactone block copolymers
WO1994025086A1 (fr) * 1993-04-27 1994-11-10 Haemonetics Corporation Appareil et procede de pherese

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSAI C -C ET AL: "SURFACE MODIFYING ADDITIVES FOR IMPROVED DEVICE-BLOOD COMPATIBILITY", ASAIO JOURNAL, vol. 40, no. 3, July 1994 (1994-07-01), pages 619 - 624, XP000498253 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763312A1 (fr) * 2013-10-28 2021-01-13 Boston Scientific Scimed, Inc. Système de gestion de fluide
US11628244B2 (en) 2013-10-28 2023-04-18 Boston Scientific Scimed, Inc. Fluid management system and methods
US12029683B2 (en) 2018-02-22 2024-07-09 Alcon Inc. Ocular implant and delivery system
CN109734854A (zh) * 2018-11-27 2019-05-10 四川大学 一种可在环氧树脂中自发构筑特定纳米结构的嵌段共聚物及其在环氧树脂高性能化中的应用
CN109734854B (zh) * 2018-11-27 2022-02-08 四川大学 一种可在环氧树脂中自发构筑特定纳米结构的嵌段共聚物及其在环氧树脂高性能化中的应用

Similar Documents

Publication Publication Date Title
US4976682A (en) Methods and apparatus for autologous blood recovery
US4806247A (en) Plasmapheresis system and method
JP2776988B2 (ja) アフェレーシス装置
US5614106A (en) Method and apparatus for collection of platelets
EP0218639B1 (fr) Systeme et procede de plasmaphorese
JP2541340B2 (ja) 血液および血液成分の白血球含量を低下させる装置および方法
EP0223126A2 (fr) Système pour collecter, traiter et restituer le sang d'un patient
US9878085B2 (en) Method for the elimination of leukocytes from blood
US8114003B2 (en) Methods for hemolysis detection in centrifugal blood separator
US20170157307A1 (en) Systems For Anticoagulating Blood
US6855120B2 (en) Apheresis system with anticoagulant flow control
Daane et al. Processing and transfusion of residual cardiopulmonary bypass volume: effects on haemostasis, complement activation, postoperative blood loss and transfusion volume
Buchholz et al. Description and use of the CS‐3000 blood cell separator for single‐donor platelet collection
Adachi et al. Management of hemostasis for pediatric patients on ventricular-assist devices
Gunaydin Clinical significance of coated extracorporeal circuits: a review of novel technologies
WO2000020053A1 (fr) Filtre pour liquide biologique et systeme correspondant
WO1998018509A1 (fr) Procede et appareil d'amelioration de la compatibilite des plaquettes dans un dispositif
JP5641417B2 (ja) アフェレーシス装置
Unger et al. Albumin and hydroxyethyl starch 130 kDa/0.4 improve filter clearance and haemocompatibility in haemo-and plasmafiltration—an in vitro study
McMillan et al. Intra-operative autologous blood management
Kocakulak et al. Effect of poly (2-methoxyethyl acrylate)-coated oxygenators on haemolysis
Perseghin et al. Donor plasmapheresis: a comparative study using four different types of equipment
EP4007917B1 (fr) Procédé de régulation de la quantité d'anticoagulant présent dans un plasma collecté après aphérèse
US12226555B2 (en) System and method for treating haemorrhagic fluid for autotransfusion
Linko An in vitro comparison of six microaggregate blood filters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998520587

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase